A5023366097- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Metastasis and carcinoma case studies
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- Viral Infections and Immunology Research
- Cancer Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Extracellular vesicles in disease
- Nanoplatforms for cancer theranostics
- Immune Cell Function and Interaction
Shanghai Pulmonary Hospital
2016-2025
Tongji University
2016-2025
Ningxia Medical University
2007-2025
Yinchuan First People's Hospital
2024
Guangzhou Medical University
2023
Central South University
2023
First Affiliated Hospital of Guangzhou Medical University
2023
State Key Laboratory of Respiratory Disease
2023
Sichuan University
2023
Xiangya Hospital Central South University
2023
Abstract Lung cancer is a highly heterogeneous disease. Cancer cells and within the tumor microenvironment together determine disease progression, as well response to or escape from treatment. To map cell type-specific transcriptome landscape of their in advanced non-small lung (NSCLC), we analyze 42 tissue biopsy samples stage III/IV NSCLC patients by single RNA sequencing present large scale, resolution profiles NSCLCs. In addition types described previous studies early cancer, are able...
Abstract The lack of response to treatment in most lung cancer patients suggests the value broadening benefit anti–PD-1/PD-L1 monotherapy. Judicious dosing antiangiogenic agents such as apatinib (VEGFR2-TKI) can modulate tumor immunosuppressive microenvironment, which contributes resistance treatment. We therefore hypothesized that inhibiting angiogenesis could enhance therapeutic efficacy PD-1/PD-L1 blockade. Here, using a syngeneic mouse model, we demonstrated low-dose alleviated hypoxia,...
Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD‐1/PD‐L1) pathway have profoundly improved clinical management of non‐small‐cell lung cancer (NSCLC). Nevertheless, superiority single‐agent PD‐1/PD‐L1 in pretreated EGFR mutant patients has turned out to be moderate. One proposed mechanism for poor response immune is an immunosuppressive tumor microenvironment. Therefore, we utilized two autochthonous ‐driven models investigate dynamic microenvironmental...
CD73 is one of the critical component in formation immunosuppressive microenvironment cancers. We aimed to provide an overview current status expression and its relationship with clinicopathlogical features prognosis different cancers.PubMed, Web Science, EMBASE Cochrane library were searched identify relevant studies. level distinct cancers characteristics investigated using online database. Meta-analyses conducted RevMan v5.0 STATA v12.0.Fourteen publications 2951 cases included. The...
ARID1A alterations would compromise mismatch repair pathway and increase the number of tumor-infiltrating lymphocytes PD-L1 expression in some cancers, which cooperate with immune checkpoint inhibitors (ICIs) treatment. However, a comprehensive analysis alteration frequency its predictive value for ICI treatment outcome cancers has not yet been investigated. Hence, we performed this pan-cancer to evaluate prevalence across >40,000 cases multiple cancer types. We found high (6.2%) ARID1A,...
To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, immune infiltrates. Whole-exome sequencing was performed on 189 surgically resected LUSC. TMB defined as sum nonsynonymous single nucleotide indel variants. CD8+ tumor-infiltrating lymphocyte (TIL) density expression were evaluated by immunohistochemistry. Six infiltrates estimated using an online database. The median...
Abstract Background As one typical cardiovascular disease, atherosclerosis severely endanger people’ life and cause burden to people health mentality. It has been extensively accepted that oxidative stress inflammation closely correlate with the evolution of atherosclerotic plaques, they directly participate in all stages atherosclerosis. Regarding this, anti-oxidation or anti-inflammation drugs were developed enable anti-oxidative therapy against However, current failed meet clinical...
Lymph node (LN) dissection is a common procedure for non-small cell lung cancer (NSCLC) to ascertain disease severity and treatment options. However, murine studies have indicated that excising tumor-draining LNs diminished immunotherapy effectiveness, though its applicability clinical patients remains uncertain. Hence, the authors aim illustrate immunological implications of LN by analyzing impact dissected (DLN) count on efficacy, propose novel 'immunotherapy-driven' strategy.
Fibronectin, an extracellular matrix protein, has been reported to be associated with heterogeneous cancer stemness, angiogenesis and progression in multiple types. However, the roles underlying mechanism of fibronectin on NSCLC need further elucidated.Public dataset such as Kaplan-Meier Plotter was used determine prognostic significance genes. The correlation different protein expression clinical xenograft tissues tested by immunohistochemistry experiment. Both vitro vivo experiments were...
PURPOSE This study aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed death-1 [PD-1] vascular endothelial growth factor [VEGF]) as first- or second-line monotherapy in advanced immunotherapy naïve non-small-cell lung cancer (NSCLC) patients. METHODS Eligible patients received intravenous 10mg/kg every 3 weeks (Q3W), 20 mg/kg 2 (Q2W), Q3W 30mg/kg Q3W. The primary endpoints were objective response rate (ORR) per RECIST v1.1. RESULTS At data...
The acquired drug resistance would influence the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer. present study aimed to investigate correlation long non-coding RNA (lncRNA) H19 with cisplatin-resistance and clinical outcome adenocarcinoma. In our study, expression cisplatin-resistant A549/DDP cells was unregulated. Knockdown restored response cisplatin. H19-mediated chemosensitivity enhancement associated metastasis, induction G0/G1 cell-cycle arrest, cell...
It is important to analyze and track Epidermal Growth Factor Receptor (EGFR) mutation status for predicting efficacy monitoring resistance throughout EGFR-tyrosine kinase inhibitors (TKIs) treatment in non-small cell lung cancer (NSCLC) patients. The objective of this study was determine the feasibility predictive utility EGFR detection peripheral blood.Plasma, serum tumor tissue samples from 164 NSCLC patients were assessed mutations using Amplification Refractory Mutation System...
Background This multicenter, retrospective study explored the value of oncogene driver subtype, programmed death‐1 ligand (PD‐L1) status, and smoking status for predicting which patients with oncogene‐driven non–small cell lung cancer (NSCLC) would benefit from treatment (PD‐1)/PD‐L1 inhibitors. Methods The clinical features, PD‐L1 tumor proportion scores, PD‐1/PD‐L1 inhibitor (PDi) outcomes (objective response rate progression‐free survival) who had advanced NSCLC Kirsten rat sarcoma 2...
Abstract Background Although oncogenic driver mutations were thought to be mutually exclusive in non‐small cell lung cancer (NSCLC), certain tumors harbor co‐occurring and represent a rare molecular subtype. The evaluation of the clinical features therapeutic response associated with this NSCLC subtype will vital for understanding heterogeneity treatment improving management these patients. Methods This retrospective study included 3774 samples from patients diagnosed NSCLC. All screened...